187 related articles for article (PubMed ID: 30157254)
1. Selective ablation of striatal striosomes produces the deregulation of dopamine nigrostriatal pathway.
Shumilov K; Real MÁ; Valderrama-Carvajal A; Rivera A
PLoS One; 2018; 13(8):e0203135. PubMed ID: 30157254
[TBL] [Abstract][Full Text] [Related]
2. The cannabinoid-1 receptor is abundantly expressed in striatal striosomes and striosome-dendron bouquets of the substantia nigra.
Davis MI; Crittenden JR; Feng AY; Kupferschmidt DA; Naydenov A; Stella N; Graybiel AM; Lovinger DM
PLoS One; 2018; 13(2):e0191436. PubMed ID: 29466446
[TBL] [Abstract][Full Text] [Related]
3. Subdivisions of the dopamine-containing A8-A9-A10 complex identified by their differential mesostriatal innervation of striosomes and extrastriosomal matrix.
Jimenez-Castellanos J; Graybiel AM
Neuroscience; 1987 Oct; 23(1):223-42. PubMed ID: 3683862
[TBL] [Abstract][Full Text] [Related]
4. Oxytocin-conjugated saporin injected into the substantia nigra of male rats alters the activity of the nigrostriatal dopaminergic system: A behavioral and neurochemical study.
Sanna F; Bratzu J; Angioni L; Pina Sorighe M; Cocco C; Argiolas A; Melis MR
Brain Res; 2021 Dec; 1773():147705. PubMed ID: 34744015
[TBL] [Abstract][Full Text] [Related]
5. The nigrostriatal pathway in the rat: A single-axon study of the relationship between dorsal and ventral tier nigral neurons and the striosome/matrix striatal compartments.
Prensa L; Parent A
J Neurosci; 2001 Sep; 21(18):7247-60. PubMed ID: 11549735
[TBL] [Abstract][Full Text] [Related]
6. Accumulation of mitochondrial DNA deletions within dopaminergic neurons triggers neuroprotective mechanisms.
Perier C; Bender A; García-Arumí E; Melià MJ; Bové J; Laub C; Klopstock T; Elstner M; Mounsey RB; Teismann P; Prolla T; Andreu AL; Vila M
Brain; 2013 Aug; 136(Pt 8):2369-78. PubMed ID: 23884809
[TBL] [Abstract][Full Text] [Related]
7. Basal Ganglia disorders associated with imbalances in the striatal striosome and matrix compartments.
Crittenden JR; Graybiel AM
Front Neuroanat; 2011; 5():59. PubMed ID: 21941467
[TBL] [Abstract][Full Text] [Related]
8. Intrastriatal injection of pre-formed mouse α-synuclein fibrils into rats triggers α-synuclein pathology and bilateral nigrostriatal degeneration.
Paumier KL; Luk KC; Manfredsson FP; Kanaan NM; Lipton JW; Collier TJ; Steece-Collier K; Kemp CJ; Celano S; Schulz E; Sandoval IM; Fleming S; Dirr E; Polinski NK; Trojanowski JQ; Lee VM; Sortwell CE
Neurobiol Dis; 2015 Oct; 82():185-199. PubMed ID: 26093169
[TBL] [Abstract][Full Text] [Related]
9. Alterations in nigral NMDA and GABAA receptor control of the striatal dopamine level after repetitive exposures to nitrogen narcosis.
Lavoute C; Weiss M; Rostain JC
Exp Neurol; 2008 Jul; 212(1):63-70. PubMed ID: 18452916
[TBL] [Abstract][Full Text] [Related]
10. Tissue engineered nigrostriatal pathway for treatment of Parkinson's disease.
Struzyna LA; Browne KD; Brodnik ZD; Burrell JC; Harris JP; Chen HI; Wolf JA; Panzer KV; Lim J; Duda JE; España RA; Cullen DK
J Tissue Eng Regen Med; 2018 Jul; 12(7):1702-1716. PubMed ID: 29766664
[TBL] [Abstract][Full Text] [Related]
11. Angiotensin II receptor binding associated with nigrostriatal dopaminergic neurons in human basal ganglia.
Allen AM; MacGregor DP; Chai SY; Donnan GA; Kaczmarczyk S; Richardson K; Kalnins R; Ireton J; Mendelsohn FA
Ann Neurol; 1992 Sep; 32(3):339-44. PubMed ID: 1416803
[TBL] [Abstract][Full Text] [Related]
12. Nigral involvement and nigrostriatal dysfunction in Huntington's disease: evidences from an MRI and SPECT study.
Kiferle L; Mazzucchi S; Unti E; Pesaresi I; Fabbri S; Nicoletti V; Volterrani D; Cosottini M; Bonuccelli U; Ceravolo R
Parkinsonism Relat Disord; 2013 Sep; 19(9):800-5. PubMed ID: 23769177
[TBL] [Abstract][Full Text] [Related]
13. The Kv7/KCNQ channel blocker XE991 protects nigral dopaminergic neurons in the 6-hydroxydopamine rat model of Parkinson's disease.
Liu H; Jia L; Chen X; Shi L; Xie J
Brain Res Bull; 2018 Mar; 137():132-139. PubMed ID: 29174294
[TBL] [Abstract][Full Text] [Related]
14. Aldehyde dehydrogenase 1-positive nigrostriatal dopaminergic fibers exhibit distinct projection pattern and dopamine release dynamics at mouse dorsal striatum.
Sgobio C; Wu J; Zheng W; Chen X; Pan J; Salinas AG; Davis MI; Lovinger DM; Cai H
Sci Rep; 2017 Jul; 7(1):5283. PubMed ID: 28706191
[TBL] [Abstract][Full Text] [Related]
15. Efferent projections from the striatal patch compartment: anterograde degeneration after selective ablation of neurons expressing mu-opioid receptor in rats.
Tokuno H; Chiken S; Kametani K; Moriizumi T
Neurosci Lett; 2002 Oct; 332(1):5-8. PubMed ID: 12377371
[TBL] [Abstract][Full Text] [Related]
16. Altered melatonin MT
Kang NH; Carriere CH; Bahna SG; Niles LP
Brain Res; 2016 Dec; 1652():89-96. PubMed ID: 27693415
[TBL] [Abstract][Full Text] [Related]
17. Apomorphine-induced alterations in striatal and substantia nigra pars reticulata glutamate following unilateral loss of striatal dopamine.
Touchon JC; Holmer HK; Moore C; McKee BL; Frederickson J; Meshul CK
Exp Neurol; 2005 May; 193(1):131-40. PubMed ID: 15817272
[TBL] [Abstract][Full Text] [Related]
18. Striatal dysfunction increases basal ganglia output during motor cortex activation in parkinsonian rats.
Belluscio MA; Riquelme LA; Murer MG
Eur J Neurosci; 2007 May; 25(9):2791-804. PubMed ID: 17561844
[TBL] [Abstract][Full Text] [Related]
19. Alterations in the nigrostriatal dopamine system after acute systemic PhIP exposure.
Agim ZS; Cannon JR
Toxicol Lett; 2018 May; 287():31-41. PubMed ID: 29378243
[TBL] [Abstract][Full Text] [Related]
20. Partial depletion of dopamine in substantia nigra impairs motor performance without altering striatal dopamine neurotransmission.
Andersson DR; Nissbrandt H; Bergquist F
Eur J Neurosci; 2006 Jul; 24(2):617-24. PubMed ID: 16903863
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
